Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009190 | 0.95 | POLB (0.43) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL19990942 | 0.85 | UBE2M (0.40) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL19990701 | 0.84 | UBE2M (0.39) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL19990700 | 0.81 | UBE2M (0.39) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL20009193 | 0.81 | UBE2M (0.38) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL23927098 | 0.81 | UBE2M (0.42) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL20009191 | 0.80 | UBE2M (0.37) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL19990707 | 0.80 | L3MBTL1 (0.43) | LMNA | |
| SCHEMBL20009194 | 0.78 | UBE2M (0.37) | UBE2MDCUN1D1LMNATSHRGAA | |
| SCHEMBL19990936 | 0.74 | PKLR (0.38) | LMNATSHRGAAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843894-B | Beta-lactamase inhibitors | 诺华股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3519419-B1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-10597396-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10065957-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | UBE2M 752/4885DCUN1D1 3834/4885LMNA 406/4885 |
| US-10597396-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | UBE2M 752/4885DCUN1D1 3834/4885LMNA 406/4885 |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | UBE2M 752/4885DCUN1D1 3834/4885LMNA 406/4885 |
| US-10065957-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | UBE2M 752/4885DCUN1D1 3834/4885LMNA 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.